The company ditches lorigerlimab in prostate cancer.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
Blackstone follows Abingworth, but why?
The company will no longer initiate a head-to-head trial of safusidenib against Voranigo.
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
Syndax’s Revuforj beats Kura in NPM1-mutated AML.
But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
